96 related articles for article (PubMed ID: 15237461)
1. Intensive therapy for aggressive lymphoma.
Bolaños-Meade J
N Engl J Med; 2004 Jul; 351(1):98-100; author reply 98-100. PubMed ID: 15237461
[No Abstract] [Full Text] [Related]
2. Intensive therapy for aggressive lymphoma.
Herishanu Y
N Engl J Med; 2004 Jul; 351(1):98-100; author reply 98-100. PubMed ID: 15237460
[No Abstract] [Full Text] [Related]
3. Intensive therapy for aggressive lymphoma.
Zomas A; Skandalis A
N Engl J Med; 2004 Jul; 351(1):98-100; author reply 98-100. PubMed ID: 15237459
[No Abstract] [Full Text] [Related]
4. Who should receive myeloablative therapy for lymphoma?
Lister TA
N Engl J Med; 2004 Mar; 350(13):1277-8. PubMed ID: 15044635
[No Abstract] [Full Text] [Related]
5. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
Schmitz N; Kloess M; Reiser M; Berdel WE; Metzner B; Dorken B; Kneba M; Trumper L; Loeffler M; Pfreundschuh M; Glass B;
Cancer; 2006 Jan; 106(1):136-45. PubMed ID: 16331635
[TBL] [Abstract][Full Text] [Related]
6. Intensive therapy for aggressive lymphoma.
Aguiar Bujanda D; Bohn Sarmiento U; Aguiar Morales J
N Engl J Med; 2004 Jul; 351(1):98-100; author reply 98-100. PubMed ID: 15229315
[No Abstract] [Full Text] [Related]
7. High-dose chemotherapy with autologous blood stem cell transplantation for aggressive subcutaneous panniculitis-like T-cell lymphoma.
Alaibac M; Berti E; Pigozzi B; Chiarion V; Aversa S; Marino F; Peserico A
J Am Acad Dermatol; 2005 May; 52(5 Suppl 1):S121-3. PubMed ID: 15858508
[No Abstract] [Full Text] [Related]
8. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.
van Imhoff GW; van der Holt B; Mackenzie MA; Van't Veer MB; Wijermans PW; Ossenkoppele GJ; Schouten HC; Sonneveld P; Steijaert MM; Kluin PM; Kluin-Nelemans HC; Verdonck LF;
J Clin Oncol; 2005 Jun; 23(16):3793-801. PubMed ID: 15809447
[TBL] [Abstract][Full Text] [Related]
9. Non-Hodgkin's lymphoma (diffuse large B cell lymphoma).
Copson E
Clin Evid; 2006 Jun; (15):30-44. PubMed ID: 16973004
[No Abstract] [Full Text] [Related]
10. A new schedule of CHOP/rituximab plus granulocyte-macrophage colony-stimulating factor is an effective rescue for patients with aggressive lymphoma failing autologous stem cell transplantation.
Olivieri A; Lucesole M; Capelli D; Gini G; Montanari M; Candela M; Troiani E; Scortechini I; Poloni A; Leoni P
Biol Blood Marrow Transplant; 2005 Aug; 11(8):627-36. PubMed ID: 16041313
[TBL] [Abstract][Full Text] [Related]
11. Role of radiation therapy in localized aggressive lymphoma.
Ng AK; Mauch PM
J Clin Oncol; 2007 Mar; 25(7):757-9. PubMed ID: 17228015
[No Abstract] [Full Text] [Related]
12. [Current status of research on B cell lymphoma chemotherapy ].
Guan ZZ; Wang SS
Zhonghua Zhong Liu Za Zhi; 2005 Dec; 27(12):760-1. PubMed ID: 16483495
[No Abstract] [Full Text] [Related]
13. Autologous peripheral blood stem cell transplantation to treat CHOP-refractory aggressive subcutaneous panniculitis-like T cell lymphoma.
Nakahashi H; Tsukamoto N; Yamane A; Saitoh T; Uchiumi H; Handa H; Karasawa M; Murakami H; Kojima M; Nojima Y
Acta Haematol; 2009; 121(4):239-42. PubMed ID: 19556752
[No Abstract] [Full Text] [Related]
14. Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group.
Arranz R; Conde E; Grande C; Mateos MV; Gandarillas M; Albo C; Lahuerta JJ; Fernández-Rañada JM; Hernández MT; Alonso N; García Vela JA; Garzón S; Rodríguez J; Caballero D;
Eur J Haematol; 2008 Mar; 80(3):227-35. PubMed ID: 18088400
[TBL] [Abstract][Full Text] [Related]
15. R-CHOP followed by consolidative autologous stem cell transplant and low dose rituxan maintenance therapy for advanced mantle cell lymphoma.
Lim SH; Esler WV; Periman PO; Beggs D; Zhang Y; Townsend M
Br J Haematol; 2008 Jul; 142(3):482-4. PubMed ID: 18510683
[No Abstract] [Full Text] [Related]
16. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
Lenz G; Dreyling M; Hoster E; Wörmann B; Dührsen U; Metzner B; Eimermacher H; Neubauer A; Wandt H; Steinhauer H; Martin S; Heidemann E; Aldaoud A; Parwaresch R; Hasford J; Unterhalt M; Hiddemann W
J Clin Oncol; 2005 Mar; 23(9):1984-92. PubMed ID: 15668467
[TBL] [Abstract][Full Text] [Related]
17. Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival--results of the German Multicenter Trial.
Weiss R; Mitrou P; Arasteh K; Schuermann D; Hentrich M; Duehrsen U; Sudeck H; Schmidt-Wolf IG; Anagnostopoulos I; Huhn D
Cancer; 2006 Apr; 106(7):1560-8. PubMed ID: 16502436
[TBL] [Abstract][Full Text] [Related]
18. High-dose therapy with autologous stem cell transplantation in first response in mantle cell lymphoma.
Vigouroux S; Gaillard F; Moreau P; Harousseau JL; Milpied N
Haematologica; 2005 Nov; 90(11):1580-2. PubMed ID: 16266909
[TBL] [Abstract][Full Text] [Related]
19. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.
Nickenig C; Dreyling M; Hoster E; Pfreundschuh M; Trumper L; Reiser M; Wandt H; Lengfelder E; Unterhalt M; Hiddemann W;
Cancer; 2006 Sep; 107(5):1014-22. PubMed ID: 16878325
[TBL] [Abstract][Full Text] [Related]
20. Pilot study of modified version of CHOP plus radiotherapy for early-stage aggressive non-Hodgkin's lymphoma of the head and neck.
Nishioka T; Tsuchiya K; Nishioka S; Kitahara T; Ohmori K; Homma A; Aoyma H; Shindoh M; Shirato H
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):847-52. PubMed ID: 15465202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
